Theravance Biopharma, Inc. (TBPH)
- Previous Close
9.22 - Open
9.14 - Bid 9.13 x 100
- Ask 9.17 x 100
- Day's Range
9.05 - 9.26 - 52 Week Range
8.21 - 11.98 - Volume
151,776 - Avg. Volume
368,390 - Market Cap (intraday)
444.324M - Beta (5Y Monthly) 0.35
- PE Ratio (TTM)
-- - EPS (TTM)
-1.00 - Earnings Date May 6, 2024 - May 10, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
15.40
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
www.theravance.comRecent News: TBPH
Performance Overview: TBPH
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TBPH
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TBPH
Valuation Measures
Market Cap
447.24M
Enterprise Value
393.97M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.87
Price/Book (mrq)
2.10
Enterprise Value/Revenue
6.86
Enterprise Value/EBITDA
-9.23
Financial Highlights
Profitability and Income Statement
Profit Margin
-96.11%
Return on Assets (ttm)
-6.73%
Return on Equity (ttm)
-16.86%
Revenue (ttm)
57.42M
Net Income Avi to Common (ttm)
-55.19M
Diluted EPS (ttm)
-1.00
Balance Sheet and Cash Flow
Total Cash (mrq)
102.43M
Total Debt/Equity (mrq)
23.08%
Levered Free Cash Flow (ttm)
-13.89M